Page 1. DEFINITIONS/INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 3 2. RECONCILIATION OF RIGHTS 4 2.1 The March 30 Agreement 4 2.2 Certain Rights to Improvements and Trademarks 5 2.3 Packaging and Labeling Requirements 5 3. TRANSITION...Transition/Termination Agreement • February 28th, 2008 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • New York
This TRANSITION/TERMINATION AGREEMENT (the “Agreement”) dated the 19th day of October 2007 with respect to the AGREEMENT TO DEVELOP, SUPPLY AND MARKET ATG – FRESENIUS NORTH AMERICA dated as of the 30th day of March, 2006 (the “March 30 Agreement”), is entered into by and between FRESENIUS BIOTECH GmbH, a company organized under the laws of the Federal Republic of Germany having a principal place of business at Am Haag 6-7, 82166 Graefelfing, Germany, hereinafter referred to as “FRESENIUS” and NABI BIOPHARMACEUTICALS, a corporation organized under the laws of Delaware having a principal place of business at 5800 Park of Commerce Blvd. N.W., Boca Raton, Florida 33487 USA, hereinafter referred to as “NABI”.
